CSX Stock Recent News CSX Corp (CSX) 36.79 11/14/2014 17:49:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
CSX Corp (CSX) 36.79 $CSX

Norfolk Southern Corp.: Wait For A Better Price
Minutemen - Seeking Alpha - Fri Nov 14, 2:04AM CST
Barron's recently had a bullish article on Norfolk Southern Corporation (NYSE: NSC ) in which they forecast a potential 12% rise in share price from its recent price of around $112. The forecast is based primarily on the trend for NSC in reducing...
NSC: 116.03 (+0.58), KSU: 125.88 (+1.26), CP: 204.56 (-2.15), CSX: 36.79 (+0.16), UNP: 120.71 (+0.46)

Does The End Of QE Portend A New Beginning For Income Investors?
Adam Aloisi - at Seeking Alpha - Thu Nov 13, 11:48AM CST

KO: 42.73 (-0.06), JNJ: 108.16 (-0.91), BBT: 37.43 (-0.15), LHO: 38.96 (-0.24), BP: 40.94 (+0.27), PG: 88.11 (-0.49), CVX: 116.32 (-0.13), CSX: 36.79 (+0.16), SUSQ: 13.15 (+0.09), RLJ: 32.01 (+0.17), FULT: 12.26 (-0.03), UNP: 120.71 (+0.46)

CSX CFO Reiterates Expectations And Strategy For Long-Term Value Creation
PR Newswire - Wed Nov 12, 10:02AM CST
CSX (NYSE: CSX) has taken a number of actions to overcome the transition in the energy markets in recent years, emerging a stronger company that is better positioned to capitalize on momentum across nearly all the markets it serves, Chief Financial Officer Fredrik Eliasson told investors and analysts at the Baird Global Industrials Conference today in Chicago.
CSX: 36.79 (+0.16)

Railroads Grow Faster Than The Economy
Michael Hooper - at Seeking Alpha - Tue Nov 11, 6:07AM CST

NSC: 116.03 (+0.58), SPY: 204.24 (+0.05), CNI: 70.76 (-0.39), KSU: 125.88 (+1.26), CP: 204.56 (-2.15), IYT: 162.55 (-0.14), CSX: 36.79 (+0.16), BRK.B: 145.52 (-0.77), UNP: 120.71 (+0.46)

Look for Shares of CSX to Potentially Pullback after Yesterday's 3.13% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:00PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $35.60 to a high of $36.58. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $35.58 on volume of 7.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CSX: 36.79 (+0.16)

CSX Rises 3.13% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:00PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $35.60 to a high of $36.58. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $35.58 on volume of 7.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CSX: 36.79 (+0.16)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 24.38 (+0.09), KMI: 39.37 (+0.99), HK: 3.10 (+0.06), KSS: 57.12 (+1.05), GE: 26.46 (+0.04), LMT: 186.60 (-1.37), AVAV: 29.18 (-0.63), WMT: 82.96 (+0.02), SNE: 20.64 (+0.23), M: 62.05 (+0.48), SDRL: 20.78 (+0.13), T: 35.90 (+0.29), W: 21.57 (-0.44), OPK: 8.29 (-0.05), QCOM: 70.85 (+0.20), TWTR: 41.85 (+1.81), EPR: 56.00 (-0.73), AAPL: 114.18 (+1.36), HSIC: 130.15 (-0.13), CSCO: 26.32 (+0.64), WFM: 47.11 (+0.39), CY: 10.04 (+0.06), MU: 32.62 (-0.32), SWKS: 62.80 (+2.09), IRM: 37.69 (-0.68), BAC: 17.14 (-0.08), MO: 48.78 (-0.67), CSX: 36.79 (+0.16), WWAV: 36.56 (+0.42), GILD: 102.06 (-2.14), TXN: 51.63 (+0.45), BPL: 79.34 (+0.19), JCP: 7.38 (+0.28), JWN: 74.17 (+0.92), BABA: 115.10 (+0.26)

Next Resistance Level for CSX (CSX) is $35.60
Comtex SmarTrend(R) - Fri Nov 07, 10:39AM CST
Shares of CSX (NYSE:CSX) opened today above their pivot of $35.00 and have already reached the first level of resistance at $35.36. Investors may be interested in a cross of the next upside pivot targets of $35.60 and $36.19.
CSX: 36.79 (+0.16)

October Railroad Report: Keep Rolling On
Investor RockieK - at Seeking Alpha - Fri Nov 07, 10:00AM CST

NSC: 116.03 (+0.58), CNI: 70.76 (-0.39), KSU: 125.88 (+1.26), CP: 204.56 (-2.15), CSX: 36.79 (+0.16), BRK.A: 218,023.00 (-1,277.00), UNP: 120.71 (+0.46)

Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled?
Adam Aloisi - at Seeking Alpha - Thu Nov 06, 1:52PM CST

KO: 42.73 (-0.06), BDX: 129.20 (-0.11), HD: 98.24 (-0.76), AMT: 99.53 (-0.42), AMGN: 157.68 (-3.17), O: 45.70 (-0.47), MO: 48.78 (-0.67), CSX: 36.79 (+0.16), LUV: 38.95 (-0.51), T: 35.90 (+0.29), JNJ: 108.16 (-0.91), RCL: 69.57 (+0.58), V: 248.84 (-2.08), QCOM: 70.85 (+0.20), MCD: 96.21 (+0.73), PG: 88.11 (-0.49), MSFT: 49.58 (-0.03), CVX: 116.32 (-0.13), AAPL: 114.18 (+1.36), WAG: 66.93 (-0.03)

CSX Concludes Racketeering and Fraud Litigation Against Asbestos Lawyers
PR Newswire - Thu Nov 06, 11:42AM CST
CSX Transportation today announced that it has resolved the final stages of its racketeering and fraud lawsuit against asbestos attorneys Robert N. Peirce Jr. and Louis A. Raimond, and radiologist Dr. Ray Harron. As part of the settlement, the West Virginia jury's verdict stands and CSX will be paid $7.3 million to satisfy the trial court judgment entered against the lawyers and doctor on September 25, 2013, and in resolution of disputed motions for attorney fees and costs.
CSX: 36.79 (+0.16)

Dividend Contenders, Future Champions Or Future Failures: Part 5
Stan Stafford - at Seeking Alpha - Wed Nov 05, 7:30PM CST

NSC: 116.03 (+0.58), CNI: 70.76 (-0.39), CSX: 36.79 (+0.16)

CSX Names Kellen Riley South Carolina Industrial Development Manager
PR Newswire - Wed Nov 05, 12:00PM CST
CSX (NYSE: CSX) today announced the appointment of Kellen Riley as its South Carolina Industrial Development Manager. In this role, Riley will be responsible for managing existing customer partnerships, helping to locate rail-served industries along the CSX network in South Carolina and identifying new development sites throughout the state.
CSX: 36.79 (+0.16)

CSX Corporation Chief Financial Officer to Address Baird's 2014 Industrial Conference
PR Newswire - Wed Nov 05, 9:00AM CST
Fredrik Eliasson, CSX Corporation (NYSE: CSX) executive vice president and chief financial officer, will address Baird's 2014 Industrial Conference in Chicago, Wednesday, November 12, at 8:00 a.m. Central time / 9:00 a.m. Eastern time.
CSX: 36.79 (+0.16)

Watch for CSX to Potentially Rebound After Falling 2.18% Yesterday
Comtex SmarTrend(R) - Tue Nov 04, 3:55PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $34.58 to a high of $35.28. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $35.02 on volume of 17.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CSX: 36.79 (+0.16)

CSX Falls 2.18% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 04, 3:55PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $34.58 to a high of $35.28. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $35.02 on volume of 17.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CSX: 36.79 (+0.16)

Federal Highway Administration Approves Construction Alternative for CSX's Virginia Avenue Tunnel Project
PR Newswire - Tue Nov 04, 3:39PM CST
The Federal Highway Administration has approved a preferred construction alternative for CSX's Virginia Avenue Tunnel project, enabling CSX to complete the tunnel's design and initiate the construction permitting process. The decision marks the completion of an extensive environmental review of the project conducted jointly with the District of Columbia Department of Transportation, which incorporates three years of input from residents, businesses and government agencies in the southeast Washington, D.C., neighborhood around the tunnel.
CSX: 36.79 (+0.16)

CSX (CSX) Crosses Pivot Point Support at $35.04
Comtex SmarTrend(R) - Tue Nov 04, 10:12AM CST
CSX (NYSE:CSX) has opened bearishly below the pivot of $35.39 today and has reached the first level of support at $35.04. Investors may be interested in a cross of the next downside pivot targets of $34.70 and $34.01.
CSX: 36.79 (+0.16)

Financial Results, Facility Opening, and Management Changes - Research Reports on Norfolk, Cardinal, CSX, Viacom and Carnival
PR Newswire - Tue Nov 04, 8:10AM CST
Today, Analysts Review released its research reports regarding Norfolk Southern Corp. (NYSE: NSC), Cardinal Health Inc. (NYSE: CAH), CSX Corporation (NYSE: CSX), Viacom, Inc. (NASDAQ: VIAB) and Carnival Corporation (NYSE: CCL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7672-100free.
NSC: 116.03 (+0.58), CCL: 41.50 (+0.60), CAH: 80.35 (-0.31), CSX: 36.79 (+0.16), VIAB: 72.96 (+1.76)

CSX Corp. Once Again Tops List of Florida's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
CSX Corp. claims six top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
CSX: 36.79 (+0.16)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading